Participants 668 826 6
patients (aged 18-75 years) with, or with high risk of, coronary heart disease were randomly assigned (1:1) to dalcetrapib 600 mg/day or placebo for 24 months
Participants 1489 1596 7
189 patients were screened and 130 randomly assigned to placebo (66 patients) or dalcetrapib (64 patients).
